EUVIMEDEUVIMED entdecken
Crossref

Different dosage forms of gonadotropin-releasing hormone agonist with endocrine therapy in premenopausal hormone receptor–positive breast cancer

Jinna Lin, Yiye Ouyang, Yudong Li, Liang Jin, Shunying Li, Yujie Liu, Yaping Yang, Qianfeng Shi, Mengdi Zhu, Zijie Cai, Jingru Wang, Nianqiu Liu und 8 weitere

JNCI: Journal of the National Cancer Institute · 01.10.2024 · 116 (10) · 1587-1597

DOI: 10.1093/jnci/djae115 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 04.06.2024. Verfasst von Jinna Lin und 19 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangz…. Hauptthemen laut MEDLINE: Breast Neoplasms, Premenopause, Aromatase Inhibitors, Gonadotropin-Releasing Hormone. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Science and Technology Program of Guangzhou.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite the wide use of a 3-month gonadotropin-releasing hormone (GnRH) agonist for ovarian function suppression in premenopausal breast cancer patients, it remains unclear whether it is as effective and safe as a 1-month GnRH agonist regimen when combined with selective estrogen receptor modulators or aromatase inhibitors, especially in younger patients.

Methods

This retrospective cohort study included 1109 premenopausal hormone receptor–positive breast cancer patients treated with GnRH agonist plus selective estrogen receptor modulator or aromatase inhibitor. The estradiol (E2) inhibition rate within 1-24 months after treatment with 1-month or 3-month GnRH agonist in cohorts and different subgroups was analyzed.

Results

Following 1:1 propensity score matching, 950 patients with a mean age of 39 years and a median follow-up of 46 months were included. Both the 1-month and 3-month groups achieved more than 90% E2 inhibition within 24 months (94.53% vs 92.84%, with a 95% confidence interval for the difference ranging from −4.78% to 1.41%), confirming the noninferiority of 3-month GnRH agonist. Both 1-month and 3-month GnRH agonist rapidly and consistently reduced E2 levels. Of the patients, 60 (6.3%) experienced incomplete ovarian function suppression, with similar rates in the 1-month and 3-month groups (5.5% vs 7.2%). Incomplete ovarian function suppression mainly occurred within the first 12 months, with age younger than 40 years and no prior chemotherapy being the risk factors. Similar disease-free survival and overall survival were found in the 1-month and 3-month groups and in patients with complete and incomplete ovarian function suppression (P > .05).

Conclusions

The ovarian function suppression with 3-month GnRH agonist was not inferior to that with 1-month GnRH agonist, regardless of age or combination with a selective estrogen receptor modulator or an aromatase inhibitor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsPremenopauseAromatase InhibitorsGonadotropin-Releasing HormoneAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleAdultRetrospective StudiesMiddle AgedSelective Estrogen Receptor ModulatorsEstradiolReceptors, EstrogenAntineoplastic Agents, HormonalTreatment OutcomeDrug Administration ScheduleTriazolesReceptors, ProgesteronePropensity ScoreNitrilesAnastrozole

Substanzen

Aromatase InhibitorsGonadotropin-Releasing HormoneSelective Estrogen Receptor ModulatorsEstradiolReceptors, EstrogenAntineoplastic Agents, HormonalTriazolesReceptors, ProgesteroneNitrilesAnastrozole

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.

ORCID-Profile: Qiang Liu

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Science and Technology Program of Guangzhou

Zitieren

APA

Lin, J., Ouyang, Y., Li, Y., Jin, L., Li, S., Liu, Y., Yang, Y., Shi, Q., Zhu, M., Cai, Z., Wang, J., Liu, N., Hu, Y., Wu, Z., Wu, M., Wong, L. L., Jiang, X., Wang, Q., Yang, W., & Liu, Q. (2024). Different dosage forms of gonadotropin-releasing hormone agonist with endocrine therapy in premenopausal hormone receptor–positive breast cancer. JNCI: Journal of the National Cancer Institute, 116(10), 1587-1597. https://doi.org/10.1093/jnci/djae115

Vancouver

Lin J, Ouyang Y, Li Y, Jin L, Li S, Liu Y, et al. Different dosage forms of gonadotropin-releasing hormone agonist with endocrine therapy in premenopausal hormone receptor–positive breast cancer. JNCI: Journal of the National Cancer Institute. 2024;116(10):1587-1597. doi:10.1093/jnci/djae115

BibTeX
@article{Lin2024,
  author = {Lin, Jinna and Ouyang, Yiye and Li, Yudong and Jin, Liang and Li, Shunying and Liu, Yujie and Yang, Yaping and Shi, Qianfeng and Zhu, Mengdi and Cai, Zijie and Wang, Jingru and Liu, Nianqiu and Hu, Yue and Wu, Zongqi and Wu, Mengzi and Wong, Lok Lam and Jiang, Xiaoting and Wang, Qi and Yang, Wang and Liu, Qiang},
  title = {Different dosage forms of gonadotropin-releasing hormone agonist with endocrine therapy in premenopausal hormone receptor–positive breast cancer},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2024},
  volume = {116},
  number = {10},
  pages = {1587--1597},
  doi = {10.1093/jnci/djae115}
}
Kostenlos starten →